President Trump and FDA commissioner Stephen Hahn at the White House in Washington on March 19, 2020 (Yuri Gripas, Sipa via AP Images)
April 21, 2020 02:03 PM EDTUpdated April 22, 10:33 AM
R&D
Coronavirus

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

John Carroll

Editor & Founder

Just weeks fol­low­ing the FDA’s emer­gency ap­proval of hy­drox­y­chloro­quine af­ter Pres­i­dent Trump re­peat­ed­ly ad­vo­cat­ed its use for Covid-19, new da­ta from a quick VA study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

As con­fi­dence falls, bio­phar­ma com­pa­nies take pre­cau­tions with Chi­nese part­ner­ships, sur­vey finds

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Fol­low­ing a piv­otal tri­al fail and lay­offs, Ovid finds it­self in a fa­mil­iar spot

J&J and Leg­end say Carvyk­ti im­proved sur­vival in ear­li­er-line mul­ti­ple myelo­ma

Sam­sung Bio pulls in $1.06B man­u­fac­tur­ing deal with un­named US phar­ma com­pa­ny

A service from the Financial Times